Shutdown Fears Push Wall Street Toward These 2 Vaccine Plays
In Monday’s Blitz Daily, we’ll take a look at biotech company Novavax Inc. as COVID-19 cases continue to rise worldwide.
Vaccine developer Novavax saw shares plummet after a string of management mishaps followed by weak earnings on Aug. 5. But the persistent uptick in delta variant cases has Wall Street traders diving deeper into their pandemic playbook. In turn, that has institutional traders aiming to leverage those headlines for some quick dip-buy profits using short-term options flow. Notably, buyers piled into the NVAX Aug. 13 $220 call, with more than 10,000 contracts trading hands…
The Blitz Tracker also spotted two more options plays seeing serious love today including a second round of buying on a familiar name ahead of its Monday earnings report…
Disclaimer & Disclosures The information in this email is intended for informational purposes only and does not guarantee specific results as there is a high degree of risk involved with trading. Also, our traders are real traders and may have financial interests in the companies discussed. Please see our Terms and Conditions for more information.
Post a Comment
Post a Comment